Given the current public health emergency, the FDA's guidance also addresses considerations regarding Emergency Use Authorization (EUA) of an investigational vaccine. This, however, should be made clear that any potential EUA for a COVID-19 vaccine must be made on a case-by-case basis. It involves a number of factors such as the characteristics of the product, target population, and the totality of the relevant, available scientific evidence.